Data from a preclinical study show that AR-42, an experimental drug, may stop cachexia associated with advanced cancers and restore muscle health, according to a study in the Journal of the National Cancer Institute. Read more and read the study abstract.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
